IGF-1 LR3
Long-acting insulin-like growth factor-1 analogue discussed in experimental growth factor and performance-related contexts, with significant safety and regulatory considerations.
This page is for general educational and informational purposes only. It is not medical advice and does not replace professional medical judgment. Always consult a qualified clinician before starting, stopping, or changing any medication or protocol.
Overview
IGF-1 LR3 is a modified form of insulin-like growth factor-1 (IGF-1) with changes that extend its half-life and alter binding to IGF-binding proteins.
It is often discussed in experimental growth factor and performance-related contexts rather than standard endocrine care.
Mechanism of action
IGF-1 receptor activation influences growth, cellular proliferation, and metabolic pathways. The LR3 modification is intended to prolong activity and modify tissue distribution.
Indications and use context
While IGF-1 biology is central to growth and metabolism, IGF-1 LR3 itself is not a standard therapeutic agent in most guidelines.
Non-regulated use raises concerns about safety, fairness in sport, and departure from evidence-based practice.
Safety and side effects
Exogenous growth factor signaling can influence glucose regulation, tissue proliferation, and potentially neoplastic risk.
Safety data for IGF-1 LR3 specifically are limited, and unsupervised use is associated with significant uncertainty.
Pharmacology and dosing considerations
IGF-1 LR3 is a long-acting analogue (half-life ~20-30 hours) that avoids binding proteins, making it much more potent than generic IGF-1.
Route: Subcutaneous or Intramuscular injection.
Protocol structure and dosage:- Dosage: 20 mcg to 50 mcg daily.
- Timing: Often administered post-workout.
- Cycle: 4 weeks on, 4 weeks off to prevent receptor downregulation.
Warning: High doses can cause hypoglycemia. Always ensure adequate carbohydrate intake around administration.
Formulations and combinations
IGF-1 LR3 appears in catalogs as a research peptide and may be mentioned in combination with other growth factors or anabolic agents, combinations that can compound risk.
Research and evidence snapshot
Published work focuses on basic receptor pharmacology and limited clinical or quasi-clinical use, often outside large randomized trials.
Frequently asked questions
Future FAQs may address how IGF-1 analogues relate to approved growth hormone and IGF therapies and why many sports and regulatory bodies restrict their use. Answers will remain educational and non-prescriptive.
Sport & Anti-Doping Warning
IGF-1 LR3 is a long-acting insulin-like growth factor analogue noted by anti-doping experts as a potent, hard-to-detect performance enhancer; it is covered under the WADA category for peptide hormones and growth factors.
- >Overview of IGF-1 analogues and related substances under the WADA List
- >Educational article describing IGF-1 LR3 and its relevance to sport
Even without many public positive tests, laboratories treat IGF-1 LR3 as a high-priority target substance in the GH–IGF axis.
Comments
Loading comments...
Get the Standard Protocols.
Join 12,000+ researchers. Receive weekly breakdowns of new compounds, safety data updates, and source verification reports.